NATCO Pharma launches lenalidomide 2.5mg and 20mg in US
NATCO Pharma said that it has launched additional strengths for the generic version of Revlimid (lenalidomide capsules), in the strengths of 2.5mg and 20mg in ... Read More
Arcellx, and Kite to jointly advance CART-ddBMCA for multiple myeloma
Arcellx, a US-based clinical-stage biotechnology company, and Kite, a Gilead company, are partnering to co-develop and co-commercialize the former’s CART-ddBCMA, a late-stage product candidate. CART-ddBCMA, ... Read More
Thermo Fisher to buy specialist protein diagnostics company Binding Site
Thermo Fisher Scientific has agreed to acquire The Binding Site Group, a UK-based specialist protein diagnostics company, for £2.25 billion ($2.6 billion) in an all-cash ... Read More
FDA approves Janssen’s TECVAYLI for multiple myeloma treatment
The Janssen Pharmaceutical Companies, a subsidiary of Johnson & Johnson, announced the US Food and Drug Administration's approval of its first bispecific T-cell engager antibody, ... Read More
Zydus Lifesciences gets FDA approval for Bortezomib for Injection
Zydus Lifesciences (previously called Cadila Healthcare) said that it has secured final approval from the US Food and Drug Administration (FDA) to market Bortezomib for ... Read More
GSK to acquire US biopharma company Sierra Oncology for $1.9bn
GlaxoSmithKline (GSK) has agreed to acquire Sierra Oncology, a California-based biopharma company, in a deal worth around $1.9 billion (£1.5 billion). As per the terms ... Read More
Harpoon Therapeutics gets FDA fast track status for HPN217 in RRMM
Harpoon Therapeutics has bagged fast track designation for HPN217 from the US Food and Drug Administration (FDA) for the treatment of certain patient population with ... Read More
Natco Pharma launches PrNAT-LENALIDOMIDE Capsules in Canada
Natco Pharma Limited has announced the Canadian launch of PrNAT-LENALIDOMIDE Capsules, a generic version of Celgene Corporation’s cancer drug Revlimid. The launch was announced earlier ... Read More
Aurobindo subsidiary Eugia gets FDA approval for Cyclophosphamide Injection
Aurobindo Pharma said that its subsidiary Eugia Pharma Specialities has secured approval from the US Food and Drug Administration (FDA) for the new drug application ... Read More
Pfizer to acquire immuno-oncology company Trillium Therapeutics for $2.2bn
US pharma giant Pfizer has agreed to acquire Trillium Therapeutics, a publicly listed Canadian clinical stage immuno-oncology company, for $18.5 per share or $2.26 billion ... Read More